ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Modag raises $14 million to test small molecule for neurodegenerative diseases

by Ryan Cross
July 5, 2019 | APPEARED IN VOLUME 97, ISSUE 27

 

09727-buscon14-anle.jpg

The German start-up Modag has raised about $14 million in series A financing to begin testing small-molecule drugs for neurodegenerative diseases in clinical studies. Modag’s lead drug candidate, called anle138b, binds toxic oligomers of α-synuclein, a protein whose aggregation is implicated in Parkinson’s disease. To start, Modag will test the compound in a rare disease called multiple system atrophy, which is similar to Parkinson’s. The company was founded in 2013 by scientists from Ludwig Maximilian University of Munich and the Max Planck Institute for Biophysical Chemistry.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment